We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

New Cell Lines Produce NIST Monoclonal Antibody for Improved Biologic Drug Manufacturing

News   Aug 01, 2018 | Original story from the National Institute of Standards and Technology (NIST)

 
New Cell Lines Produce NIST Monoclonal Antibody for Improved Biologic Drug Manufacturing

HeLa cancer cells appear green wherever mouse monoclonal antibodies (mAb) have bound to tubulin, a structural protein important in cell division. Binding to tubulin and preventing cell growth is one way that mAb drugs could kill tumors—the type of research that may benefit from the use of NIST's monoclonal antibody reference material, NISTmAb. Credit: ©EnCor Biotechnology Inc.

 
 
Advertisement
 

RELATED ARTICLES

Mutated Form of SARS-CoV-2 is Dominant, But Doesn't Make Patients Sicker, Study Says

News

In a collaborative research study, scientists show that a mutated version of SARS-CoV-2 has become the predominant form across the globe. Whilst the variant competes with the original strain, clinical data suggests that it does not make individuals sicker.

READ MORE

Safer and More Efficient Method To Deliver Gene Therapy

News

Madison researchers have developed a safer and more efficient way to deliver a promising new method for treating cancer and liver disorders and for vaccination.

READ MORE

Controlled Human Infection Models for SARS-CoV-2 Vaccine Development

News

Infecting some volunteers with COVID-19 may provide valuable insights for future rounds of vaccine testing, but would require very strict controls, argues a group of infectious disease experts in the New England Journal of Medicine.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE